엑소좀 연구 시장 평가 : 제품 및 서비스별, 적응증별, 용도별, 최종사용자별, 지역별 기회 및 예측(2017-2031년)

Global exosome research market is projected to witness a CAGR of 17.37% during the forecast period 2024-2031, growing from USD 203.44 million in 2023 to USD 732.64 million in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.

Exosomes are tiny extracellular vesicles released by cells and play an important role in intercellular communication. These vesicles consist of different biomolecules such as proteins, lipids, and nucleic acids, which can be used for diagnostic and therapeutic purposes. Its market includes various products such as detection kits, isolation kits, and characterization kits used for the analysis, purification, and isolation of exosomes. These exosomes can be used as biomarkers to diagnose diseases and monitor them, as well as for drug delivery in targeted therapies.

The global exosome research market is expected to grow rapidly due to increasing expenditure on research and development, rising prevalence of chronic diseases, rising geriatric population, and expanding technology throughout the healthcare sector. Healthcare providers and industry giants are coming together to bring out their best diagnostic approaches for patients. Funds are being raised, and a hefty amount is being invested by both government bodies and private companies. Strategic initiatives such as mergers and acquisitions, investments, and partnerships come into play when these huge companies are trying to launch or develop a new product. In August 2022, Creative Biolabs launched an advanced platform called the Nanosight platform, which is used for exosome characterization. This platform is accessible to all kinds of research and industrial customers for size distribution analysis, exosome concentration measurement, and phenotypic evaluation.

Increasing Expenditure on Research and Development

The global market for exosome research has grown significantly due to increasing research investments. With the help of this funding, scientists have now been able to study exosomes in greater detail and with greater depth, which has improved their knowledge and therapeutic applications. The development of novel technologies and methods for the isolation, analysis, and characterization of exosomes has been made possible by increased funding for exosome research. As a result, the market for exosome research has seen the development of new goods and services as well as novel uses for exosomes in the diagnosis and treatment of various diseases. The exosome research market has grown because of this broader research focus, which has also improved knowledge of the clinical uses of exosomes. Exosome-based treatments have lately been included in the pipelines of several businesses. One of the main areas of concentration for the exosome research market has been the creation of novel and enhanced exosome isolation technologies. The use of microfluidic devices for high-throughput exosome extraction and the creation of novel techniques for separating exosomes from particular cell types are examples of recent developments in this field.

For instance, Guardant Health, which specializes in precision oncology, developed a test called the Guardant360 test in 2022 that utilizes circulating tumor DNA (ctDNA), which is extracted from exosomes in the bloodstream and used to detect cancer-related mutations. This liquid biopsy test offers a non-invasive alternative to traditional tissue biopsies, allowing for the detection and monitoring of various cancer types through a simple blood draw.

Increasing Prevalence of Chronic Diseases

The global market for exosome research is being significantly impacted by the rising incidence of chronic illnesses. Millions of individuals worldwide are impacted by chronic diseases like cancer, heart disease, and neurological problems, which pose serious challenges to public health. The exosome research market is expanding as a result of exosomes' potential as therapeutic and diagnostic tools to treat different types of chronic diseases. Research is now receiving more attention due to the rise in prevalence of chronic illnesses, which presents a chance for exosomes to play a crucial role in disease monitoring, diagnosis, and therapy.

The industry is expanding because researchers are looking at exosomes' potential as medicines and biomarkers. Exosomes have shown promising results as a unique class of treatments that can transport medications and genetic material to certain cells and tissues. Exosome-based therapies and products have been developed in response to the growing need for innovative treatments brought on by the increased prevalence of chronic diseases.

Exosomes found in biological fluids can be analyzed to find biomarkers that might point to the existence of a disease. This has fueled the development of fresh exosome-based diagnostic instruments and assays, which has increased demand for exosome research. There is a huge market demand for innovative and efficient treatments as well as diagnostic instruments due to the rising incidence of chronic illnesses.

Exosome research has increased in response to demand, as exosomes have shown promise as a potential remedy for various ailments. A report published by NIH in January 2023 stated that in the US, the number of people who are above the age of 50 will increase from 137.25 million in 2020 to 221.13 million in 2050, a significant increase of 61.11%. The number of people 50 years of age and older who have at least one chronic illness is predicted to increase from 71.522 million in 2020 to 142.66 million in 2050.

Growth In Various Therapeutic Applications of Exosomes

Exosomes may be employed as a platform for therapeutic intervention for various diseases. Exosomes can be used in clinical settings as cell-free substitutes to treat a variety of illnesses and promote tissue regeneration since they can carry therapeutic cargo components without causing cellular toxicity or immunological rejection. Exosomes produced from stem cells have the benefit of using the regenerative and anti-inflammatory properties of their parent cells; as a result, respiratory virus infections can be treated with exosomal therapy. Given their natural material transportation qualities, capacity to sustain intrinsic long-term circulation, and high biocompatibility - all of which make them ideal for the delivery of a wide range of proteins, chemicals, and nucleic acids - exosomes make great drug delivery vehicles.

Exosomes have proved to be promising as intercellular communication mediators, potentially transporting functional proteins, mRNA transcripts, and miRNAs to cells all over the body, according to a few research investigations. Exosomes are biocompatible and are effective agents in a variety of conditions, including organ injuries and ailments of the heart, kidney, liver, and lungs. They are derived from specific cell types, such as mesenchymal and dendritic stem cells. Even though research on exosome uses has advanced at a fast pace, there are still several obstacles in the way of creating treatments based on exosomes, especially when it comes to producing exosome formulations because of their poor productivity and heterogeneity. But finding a way to combat this and be able to fully use their potential in a variety of ways is promising for the expansion of the exosome research market.

In April 2024, Exo Biologics, a clinical-stage biotech company, announced that it has successfully secured a total of EUR 16 million in Series A funding for the development of exosome-based therapies. These funds will be used by them to support its future and ongoing trials. It will also continue its manufacturing expansion, including upgrading its unique production platform, ExoPulse (TM), and expanding partnerships to enable pan-market access to the platform and GMP clinical grade exosomes for faster access to clinical trials.

North America Dominates the Exosome Research Market

North America accounts for the highest market shares of exosomes due to its advanced healthcare system, favorable laws, an extensive network of multinational corporations, and high level of knowledge among people about healthcare and diagnostics. Numerous government-funded studies have been carried out in the region to investigate the potential involvement of medications utilizing exosomes in various cancer types, including pancreatic cancer, melanoma, lung cancer, and breast cancer. Universities like Yale University and Michigan State University have partnered with and are being supported by companies like Merck and Exosome Diagnostic to carry out clinical trials in the US. Moreover, government funding for these endeavors is excellent. The United States is witnessing widespread use of cutting-edge micro-nanotechnologies for extracellular vesicles in immuno-oncology, spanning from immunomodulation to target-specific isolations. In the upcoming years, the market under study is anticipated to increase rapidly due to the implementation of new technologies.

Future Market Scenario (2024-2031F)

The market growth of exosome research is steadily increasing due to several factors. This market is expected to consistently grow in the future because of how promising its uses can be in developing diagnostics and therapeutics. As the geriatric population increases, so will the number of patients. People are widely accepting new diagnostic methods and developments to combat their illnesses. For example, according to the Lab Chip Journal, in July 2022, the United States experienced a wide adoption of emerging micro-nanotechnologies for extracellular vesicles in immuno-oncology, ranging from target-specific isolations to immunomodulation.

Key Players Landscape and Outlook

Several companies such as Thermo Fisher Scientific, Inc, Qiagen, Lonza Group Ltd, System Biosciences, LLC, Bio-Techne Corporation, Danaher Corporation, Amsbio Holdings Limited, RoosterBio, Inc., Miltenyi Biotec India Private Limited, Norgen Biotek Corp., etc. are expanding their businesses by planning and adopting new strategies. They are adopting new strategic initiatives regarding exosome research to help researchers and increase their presence in the market. New product launches, agreements based on contracts, acquisitions and mergers, investments, and partnerships are a few ways through which they are trying to achieve the same.

In July 2022, Cells for Cells, a clinical-stage biotech pioneering allogeneic stem cell and stem-cell-derived therapeutics for high-impact chronic diseases, announced a 6-month follow-up of the groundbreaking clinical data from the first-ever patient dosed with an exosome-produced therapy for osteoarthritis.

In April 2022, Global Stem Cells Group (GSCG) announced the launch of its new product with new lyophilized exosome technology. Global Stem Cells Group's new product line includes innovative anti-aging products that can regenerate cells and tissues in the body.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Exosome Research Market Outlook, 2017-2031F

• 4.1.Market Size & Forecast
  • 4.1.1.By Value
  • 4.1.2.By Volume
• 4.2.By Product and Service
  • 4.2.1.Kits and Reagents
  • 4.2.2.Instruments
  • 4.2.3.Services
• 4.3.By Indication Type
  • 4.3.1.Cancer
  • 4.3.2.Neurodegenerative Diseases
  • 4.3.3.Cardiovascular Diseases
  • 4.3.4.Infectious Diseases
  • 4.3.5.Others
• 4.4.By Application Type
  • 4.4.1.Biomarkers
  • 4.4.2.Vaccine Development
  • 4.4.3.Tissue Regeneration
  • 4.4.4.Others
• 4.5.By End-user
  • 4.5.1.Pharmaceutical and Biotechnological Companies
  • 4.5.2.Hospitals and Clinical Testing Laboratories
  • 4.5.3.Academic and Research Institutes
• 4.6.By Region
  • 4.6.1.North America
  • 4.6.2.Europe
  • 4.6.3.Asia-Pacific
  • 4.6.4.South America
  • 4.6.5.Middle East and Africa
• 4.7.By Company Market Share (%), 2023

5.Global Exosome Research Market Outlook, By Region, 2017-2031F

• 5.1.North America*
  • 5.1.1.Market Size & Forecast
    • 5.1.1.1.By Value
    • 5.1.1.2.By Volume
  • 5.1.2.By Product and Service
    • 5.1.2.1.Kits and Reagents
    • 5.1.2.2.Instruments
    • 5.1.2.3.Services
  • 5.1.3.By Indication Type
    • 5.1.3.1.Cancer
    • 5.1.3.2.Neurodegenerative Diseases
    • 5.1.3.3.Cardiovascular Diseases
    • 5.1.3.4.Infectious Diseases
    • 5.1.3.5.Others
  • 5.1.4.By Application Type
    • 5.1.4.1.Biomarkers
    • 5.1.4.2.Vaccine Development
    • 5.1.4.3.Tissue Regeneration
    • 5.1.4.4.Others
  • 5.1.5.By End-user
    • 5.1.5.1.Pharmaceutical and Biotechnological Companies
    • 5.1.5.2.Hospitals and Clinical Testing Laboratories
    • 5.1.5.3.Academic and Research Institutes
  • 5.1.6.United States*
    • 5.1.6.1.Market Size & Forecast
      • 5.1.6.1.1.By Value
      • 5.1.6.1.2.By Volume
    • 5.1.6.2.By Product and Service
      • 5.1.6.2.1.Kits and Reagents
      • 5.1.6.2.2.Instruments
      • 5.1.6.2.3.Services
    • 5.1.6.3.By Indication Type
      • 5.1.6.3.1.Cancer
      • 5.1.6.3.2.Neurodegenerative Diseases
      • 5.1.6.3.3.Cardiovascular Diseases
      • 5.1.6.3.4.Infectious Diseases
      • 5.1.6.3.5.Others
    • 5.1.6.4.By Application Type
      • 5.1.6.4.1.Biomarkers
      • 5.1.6.4.2.Vaccine Development
      • 5.1.6.4.3.Tissue Regeneration
      • 5.1.6.4.4.Others
    • 5.1.6.5.By End-user
      • 5.1.6.5.1.Pharmaceutical and Biotechnological Companies
      • 5.1.6.5.2.Hospitals and Clinical Testing Laboratories
      • 5.1.6.5.3.Academic and Research Institutes
  • 5.1.7.Canada
  • 5.1.8.Mexico

All segments will be provided for all regions and countries covered

• 5.2.Europe
  • 5.2.1.Germany
  • 5.2.2.France
  • 5.2.3.Italy
  • 5.2.4.United Kingdom
  • 5.2.5.Russia
  • 5.2.6.Netherlands
  • 5.2.7.Spain
  • 5.2.8.Turkey
  • 5.2.9.Poland
• 5.3.Asia-Pacific
  • 5.3.1.India
  • 5.3.2.China
  • 5.3.3.Japan
  • 5.3.4.Australia
  • 5.3.5.Vietnam
  • 5.3.6.South Korea
  • 5.3.7.Indonesia
  • 5.3.8.Philippines
• 5.4.South America
  • 5.4.1.Brazil
  • 5.4.2.Argentina
• 5.5.Middle East and Africa
  • 5.5.1.Saudi Arabia
  • 5.5.2.UAE
  • 5.5.3.South Africa

6.Market Mapping, 2023

• 6.1.By Product and Service
• 6.2.By Indication Type
• 6.3.By Application Type
• 6.4.By End-user
• 6.5.By Region

7.Macro Environment and Industry Structure

• 7.1.Demand Supply Analysis
• 7.2.Import Export Analysis
• 7.3.Value Chain Analysis
• 7.4.PESTEL Analysis
  • 7.4.1.Political Factors
  • 7.4.2.Economic System
  • 7.4.3.Social Implications
  • 7.4.4.Technological Advancements
  • 7.4.5.Environmental Impacts
  • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5.Porter's Five Forces Analysis
  • 7.5.1.Supplier Power
  • 7.5.2.Buyer Power
  • 7.5.3.Substitution Threat
  • 7.5.4.Threat From New Entrant
  • 7.5.5.Competitive Rivalry

8.Market Dynamics

• 8.1.Growth Drivers
• 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

• 9.1.Clinical Trials
• 9.2.Regulatory Approvals
• 9.3.Innovations/Emerging Technologies

10.Key Players Landscape

• 10.1.Competition Matrix of Top Five Market Leaders
• 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4.SWOT Analysis (For Five Market Players)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

• 13.1.Thermo Fisher Scientific, Inc
  • 13.1.1.Company Details
  • 13.1.2.Key Management Personnel
  • 13.1.3.Products and Services
  • 13.1.4.Financials (As reported)
  • 13.1.5.Key Market Focus and Geographical Presence
  • 13.1.6.Recent Developments
• 13.2.Qiagen
• 13.3.Lonza Group Ltd
• 13.4.System Biosciences, LLC
• 13.5.Bio-Techne Corporation
• 13.6.Danaher Corporation
• 13.7.Amsbio Holdings Limited
• 13.8.RoosterBio, Inc.
• 13.9.Miltenyi Biotec India Private Limited
• 13.10.Norgen Biotek Corp.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer